Q32 Bio Inc. — Director's Dealing 2020

Dec 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2020-12-14

Reporting Person: PARMAR KUSH (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-14	Common Stock	S	151138	$13.0609	Disposed	5163346	Indirect
2020-12-14	Common Stock	S	328862	$11.88	Disposed	4834484	Indirect
2020-12-14	Common Stock	S	6297	$13.0609	Disposed	215138	Indirect
2020-12-14	Common Stock	S	13703	$11.88	Disposed	201435	Indirect

Footnotes

F1: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F2: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.